The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC
ConditionNasopharyngeal Carcinoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorChongqing University Cancer Hospital
About this trial
Camrelizumab is an antibody targeting programmed death receptor 1 (PD-1) and its ligand programmed death-ligand 1 (PD- L1) that is designed to boost the immune system. It does this by allowing immune cells to fight the cancer. Stereotactic body radiotherapy is a potential immunostimulatory therapy that may amplify antitumor response when combined with camrelizumab.
Eligibility criteria
Qualifiers
Signed Written Informed Consent
Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines.
Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other study obligations.
The peripheral blood EBV DNA copy number can be obtained.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Camrelizumab
- Stereotactic body radiotherapy
Treatment groups
39 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov